iSpecimen Inc.

iSpecimen Inc. filed an Amendment No. 1 to its Form S-1 registration statement for a public offering of up to 1,515,152 shares of common stock and up to 1,515,152 pre-funded warrants. The assumed public offering price is $2.64 per share, with pre-funded warrants exercisable at $0.0001 per share. The amendment clarifies the use of proceeds, noting that "outstanding debt" refers to accounts payable and accrued obligations, and allocates approximately $700,000 for potential acquisitions.

iSpecimen Inc. filed an S-1 registration statement for a proposed offering of up to 1,544,402 shares of common stock and pre-funded warrants. The offering will be on a best-efforts basis with an assumed public offering price of $2.59 per share. This follows a May 2026 private placement that raised approximately $2.5 million and a 1-for-40 reverse stock split effective April 27, 2026.

iSpecimen Inc. received a notice from Nasdaq on May 29, 2026, indicating non-compliance with the minimum stockholders' equity requirement of $2,500,000 for continued listing on the Nasdaq Capital Market. The company's reported stockholders' equity was $814,038 as of March 31, 2026, and it also fails to meet alternative listing standards. The notice does not immediately affect the trading of its common stock, and iSpecimen plans to submit a compliance plan within 45 days.

iSpecimen Inc. reported a significant decline in Q1 2026 revenue to $156,009, an 85.2% decrease from $1,057,510 in Q1 2025, while its net loss widened by 37.2% to $2.28 million. The company also disclosed a negative working capital of $2.12 million and an accumulated deficit of $84.63 million as of March 31, 2026, raising substantial doubt about its ability to continue as a going concern. Management is implementing cost-cutting measures, including workforce reductions, and plans to generate additional revenue, but cannot assure success.

iSpecimen Inc. announced the pricing and closing of a private placement, raising approximately $2.5 million in gross proceeds. The company issued a combination of common stock and pre-funded warrants to accredited investors, with proceeds earmarked for working capital and marketing. Additionally, iSpecimen Inc. has regained compliance with The Nasdaq Capital Market's minimum bid price requirement, resolving a previously disclosed listing issue.

iSpecimen Inc. announced the pricing of a private placement with accredited investors, aiming to raise approximately $2.5 million in gross proceeds. The offering involves the issuance of 488,281 shares of common stock at $5.12 per share, with an option for certain purchasers to receive pre-funded warrants at $5.1199 each. The net proceeds are intended for working capital purposes, including up to $900,000 for marketing expenses, and the closing is anticipated around May 11, 2026.

iSpecimen Inc. announced a 1-for-40 reverse stock split of its common stock, effective April 27, 2026, with trading on a split-adjusted basis beginning April 28, 2026. This action is intended to increase the per share trading price to attract institutional investors and ensure compliance with Nasdaq's minimum bid price requirement. The company also ratified a prior 1-for-20 reverse stock split from September 2024, which had not been properly filed at the time.

iSpecimen Inc. has repeatedly adjourned its 2025 Annual Meeting of Stockholders due to a lack of quorum. The meeting, initially scheduled for December 31, 2025, was reconvened and adjourned four times through April 10, 2026. The company now plans to reconvene the Annual Meeting on May 8, 2026, with the record date for stockholders remaining November 3, 2025, and no changes to the proposals.

iSpecimen Inc. announced a significant operational improvement, achieving an 85% reduction in human biospecimen shipping time. The company implemented a streamlined shipping model that facilitates direct shipment of biospecimens from supplier sites to customers, both domestically and internationally. This new approach eliminates the need for centralized hub processing, which previously added 7-14 days to transit times, thereby simplifying logistics and enhancing efficiency.